Motus GI Holdings, Inc.
|
(Name of Issuer)
|
Common stock, par value $0.0001 per share
|
(Title of Class of Securities)
|
62014P108
|
(CUSIP Number)
|
Samuel A. Waxman
|
Paul Hastings LLP
|
200 Park Avenue
|
New York, NY 10166
|
(Name, Address and Telephone Number of Person Authorized to
|
Receive Notices and Communications)
|
December 31, 2019
|
(Date of Event Which Requires Filing of this Statement)
|
1
|
NAMES OF REPORTING PERSONS
Orchestra BioMed, Inc. |
|||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) ☐ (b) ☐
|
|||
3
|
SEC USE ONLY
|
|||
4
|
SOURCE OF FUNDS (SEE INSTRUCTIONS)
OO |
|||
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
☐
|
|||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
|||
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
|
7
|
SOLE VOTING POWER
2,051,498 (1) |
||
8
|
SHARED VOTING POWER
0 |
|||
9
|
SOLE DISPOSITIVE POWER
2,051,498 (1) |
|||
10
|
SHARED DISPOSITIVE POWER
0 |
|||
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,051,498 (1) |
|||
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
☐ |
|||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.1% |
|||
14
|
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO |
|||
Nature of
Transaction |
Date
|
Number of
Shares |
Weighted
Average Price Per Share |
|||||||
Private Acquisition(1)
|
12/31/19
|
51,498
|
$
|
3.39
|
Dated: February 26, 2020
|
Orchestra BioMed, Inc.
|
||
By:
|
/s/ David P. Hochman
|
||
Name: David P. Hochman
Title: Chief Executive Officer |
Name
|
Residence or Business
Address
|
Present Principal Occupation
(“PPO”)
|
Name, Principal Business and
Address of PPO
|
David P. Hochman
|
150 Union Square Drive
New Hope, PA 18938
|
Chief Executive Officer of the Reporting Person
Formerly Managing Partner of OMV LLC (as of 12/31/2019)
|
OMV LLC
150 Union Square Drive
New Hope, PA 18938
OMV was an investment firm managing funds whose principal holdings were securities of the Reporting Person and the issuer. The Reporting Person continues to hold securities of the issuer.
|
Darren R. Sherman
|
150 Union Square Drive
New Hope, PA 18938
|
President and Chief Operating Officer of the Reporting Person
Formerly Managing Partner of OMV LLC (as of 12/31/2019)
|
OMV LLC
150 Union Square Drive
New Hope, PA 18938
OMV was an investment firm managing funds whose principal holdings were securities of the Reporting Person and the issuer. The Reporting Person continues to hold securities of the issuer.
|
C. Evan Ballantyre
|
150 Union Square Drive
New Hope, PA 18938
|
Chief Financial Officer of the Reporting Person
|
Geoffrey W. Smith
|
11 Time Square
Suite 1500A
New York, NY 10036
|
Managing Partner of Digitalis Ventures, LLC, a Delaware limited liability company
|
Digitalis Ventures, LLC
11 Times Square
Suite 1500A
New York NY 10036
Digitalis Ventures is a venture capital firm that invests in fundamental new ideas in math and science to address complex health problems.
|
Jason Aryeh
|
34 Sumner Road
Greenwich, CT 06831 |
Managing General Partner of JALAA Equities, LP, a Connecticut Limited Partnership
|
JALAA Equities LP
34 Sumner Road
Greenwich, CT 06831 JALAA Equities is a private hedge fund focused on the biotechnology and medical device sections
|
Eric S. Fain, M.D.
|
3900 Essex Lane
Houston, TX 77027
|
President and Chief Executive Officer of Procyrion, Inc., a Texas corporation
|
Procyrion, Inc.
3900 Essex Lane
Houston, TX 77027
Procyrion is a medical device company focused on the treatment of heart failure through a development of a safe and innovate percutaneous mechanical circulatory support device.
|
Eric A. Rose, M.D.
|
31 East 62nd Street
New York, NY 10065
|
Executive Chairman of the Board of Directors of SIGA Technologies, Inc., a Delaware corporation
|
SIGA Technologies
31 East 62nd Street
New York, NY 10065
SIGA Technologies is a commercially-staged pharmaceutical company focused on serious unmet medical needs and bio threats.
|
Name
|
Nature of
Transaction |
Date
|
Number of
Shares |
Weighted
Average Price Per Share |
||||||||
Hochman & Sherman
|
Private Disposition(1)
|
12/31/19
|
51,498
|
$
|
3.39
|
|||||||
Hochman
|
Acquisition from the Issuer(2)
|
2/6/20
|
20,000
|
$
|
0.00
|
|||||||
Sherman
|
Acquisition from the Issuer(2)
|
2/6/20
|
12,500
|
$
|
0.00
|
|||||||
Hochman
|
Acquisition from the Issuer(3)
|
2/6/20
|
20,000
|
$
|
0.00
|
|||||||
Sherman
|
Acquisition from the Issuer(3)
|
2/6/20
|
12,500
|
$
|
0.00
|